-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, M6/8OVHnApZMRz+r6pr85wH7fasg1NQtqypnc93/TH7sHKrjJv/poRrVR6PIlVu+ sXD18PT2tXOdPH5pDeqM2A== 0000936392-98-001314.txt : 19981002 0000936392-98-001314.hdr.sgml : 19981002 ACCESSION NUMBER: 0000936392-98-001314 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980930 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIDAK PHARMACEUTICALS CENTRAL INDEX KEY: 0000858803 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330314804 STATE OF INCORPORATION: CA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: SEC FILE NUMBER: 000-18734 FILM NUMBER: 98718935 BUSINESS ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 93121-3016 BUSINESS PHONE: 6195580364 MAIL ADDRESS: STREET 1: 9393 TOWN CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 93121-3016 DEFA14A 1 DEFINITIVE ADDITIONAL MATERIAL 1 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [X] Definitive Additional Materials [ ] Soliciting Material Pursuant to Section240.14a-11(c) or Section240.14a-12 LIDAK PHARMACEUTICALS - -------------------------------------------------------------------------------- (Name of Registrant as Specified In Its Charter) - -------------------------------------------------------------------------------- (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: [ ] Fee paid previously with preliminary materials. [ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 2 CONTACT: The Dilenschneider Group Bob Stone/Ken DiPaola 212/922-0900 Gregory P. Hanson, CFO 619/558-0364 x 210 FOR IMMEDIATE RELEASE LIDAK PHARMACEUTICALS FILES PROXY WITH THE SEC - WILL ASK SHAREHOLDERS TO APPROVE CORPORATE NAME CHANGE TO AVANIR PHARMACEUTICALS San Diego, CA: October 1, 1998: LIDAK Pharmaceuticals (NASDAQ: LDAKA) has filed its definitive proxy with the Securities and Exchange Commission, relating to a proposal approved by its Board of Directors that would change the company's corporate name to Avanir Pharmaceuticals. The name change will require an amendment to the company's articles of incorporation and must be approved by a majority of its shareholders. A special meeting of the shareholders has been scheduled for November 20, 1998 at 1:30 p.m. at LIDAK's corporate headquarters, 9393 Towne Centre Drive, Suite 200, San Diego, California. "We have made significant changes in our executive management and commercialization strategy", said president and CEO Gerald J. Yakatan, Ph.D. "To emphasize the importance of these changes to our shareholders and our business partners, we are proposing to change the Company's name to Avanir, which comes from the French word meaning `the future'. The new name reflects our re-positioned company and emphasizes the bright future we are working towards". 3 Avanir Page 2 The name change will not affect the validity of currently outstanding stock certificates nor will shareholders be required to surrender or exchange stock certificates currently held. The company has reserved the new ticker symbol "AVNR" with the Nasdaq Stock Market. LIDAK Pharmaceuticals develops therapeutic products for the treatment of virally-caused diseases, allergy and asthma. The company filed a new drug application (NDA) for its first product n-docosanol 10% cream, a topical treatment for oral facial herpes, with the FDA in December 1997. A decision by the FDA is anticipated in the fourth quarter 1998. LIDAK is currently finalizing its product launch plans including possible co-promotional agreements to assist with the marketing of the drug should it receive FDA approval. The company is also seeking in-licensing agreements with other pharmaceutical companies for late stage products to complete its drug pipeline. ### The information contained in this press release, including any forward looking statements contained herein, should be reviewed in conjunction with the Company's Annual Report on Form 10-K and other publicly available information regarding the Company, copies of which are available from the Company upon request. Such publicly available information sets forth many risks and uncertainties related to the Company's business and such statements, including risks and uncertainties related to drug development, clinical trials and litigation. Final decisions made by the FDA, other regulatory agencies and the courts are unpredictable and outside of the influence and/or control of the Company. -----END PRIVACY-ENHANCED MESSAGE-----